Financing ·
Inovio prices $75M public offering of common stock and pre-funded warrants at $1.05 per share
INOInovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals priced an underwritten public offering of 58,747,235 shares of common stock at $1.05 per share and pre-funded warrants to purchase up to 12,681,337 additional shares at $1.049 per warrant. The company granted the underwriters a 30-day option to purchase an additional 10,714,285 shares, which was exercised in full on November 6, 2026. Net proceeds are expected to be approximately $80.5 million after deducting underwriting discounts and estimated offering expenses. The offering closed on or about November 9, 2026. Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines.